<DOC>
	<DOCNO>NCT00972426</DOCNO>
	<brief_summary>The primary objective clinical study evaluate efficacy safety Mikelan LA eye drop 2 % ( per day ) intra-ocular pressure decrease .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety Effects Using Mikelan® LA Ophthalmic Solution ( OS ) 2 % Versus Timoptol® XE Ophthalmic Solution ( OS ) 0.5 % Ocular Hypertension Patients</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Latanoprost</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<mesh_term>Carteolol</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>1 . Male female outpatient primary openangle glaucoma ocular hypertension ; 2 . Subjects receive Latanoprost least 4 week , end screen period , subject 's IntraOcular Pressure ≧18mmHg ( choice one eye possible ) , Investigator judge reduction IOP insufficient individual subject . 3 . Aged ≧ 20 ≦80 year old give informed consent study . 1 . Hypersensitivity either oral topical betablocker therapy ophthalmic solution use study ; 2 . Patients wear contact lens ; 3 . Patients severe dry eye ; 4 . Patients ophthalmic surgery include cataract surgery , trabeculotomy trabeculectomy within three month study start ; 5 . Patients laser trabeculoplasty within 2 month start study ; 6 . Patients corneal contamination , acute ophthalmic infection , inflammatory ophthalmic disorder 2 month start study ; 7 . Patients herpetic keratitis corneal ulcer within 2 month start study ; 8 . Patient receive systemic administration drug may effect IOP ; 9 . Patients poorly control heart failure , sinus bradycardia , atrioventricular block ( 1 2 grade ) , cardiogenic shock ; 10 . Patients brochial asthma , bronchospasm severe chronic obstructive pulmonary disease history thereof ; 11 . Patients poorly control diabetes diabetic ketoacidosis metabolic acidosis ; 12 . Patients aortic stenosis , Raynaud 's syndrome , intermittent claudication , pheochromocytoma ; 13 . Patients myasthenia gravis ; 14 . Patients severe hepatic renal disorder judge investigator ; 15 . Patients confirm potential pregnancy , current lactation , wish become pregnant study period ; 16 . Patients treatment investigational drug give informed consent ; 17 . Patients significant alcohol , drug medication abuse judged investigator ; 18 . Patients investigator judge subject inappropriate clinical study ( e.g. , patient severe complication )</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2011</verification_date>
</DOC>